Arrowhead Pharmaceuticals recently announced that the European Commission (EC) has granted marketing authorisation for Redemplo (plozasiran), an innovative apolipoprotein C III (apoC-III) inhibitor already approved in the US for the treatment of adults with familial chylomicronemia syndrome (FCS). The approval was supported by Phase III data demonstrating substantial reductions in triglyceride levels and the incidence of acute pancreatitis, addressing a significant unmet need in this rare genetic disorder. These findings position Redemplo as a promising new treatment option for FCS and may improve patient access to targeted therapy across the EU.
FCS is a rare genetic disorder characterised by severely elevated triglyceride levels due to impaired chylomicron metabolism, placing patients at high risk of recurrent acute pancreatitis and other complications. Current treatment options remain limited, as conventional triglyceride-lowering therapies, including fibrates and omega-3 fatty acids, alongside dietary management are often insufficient to achieve target triglyceride levels or adequately reduce the risk of acute pancreatitis. This highlights the need for more effective therapies for the treatment of FCS.
The Phase III PALISADE study evaluated the efficacy and safety of Redemplo in adults with FCS. At month 10, median triglyceride levels were reduced by 80% with Redemplo 25mg; in a pooled analysis across all doses, the incidence rate of acute pancreatitis was reduced by 83%. These findings demonstrate the potential of Redemplo to improve the management of FCS by targeting both severe triglyceride elevations and the associated burden of acute pancreatitis. The substantial triglyceride reductions observed with Redemplo represent an important advance over conventional triglyceride-lowering treatments, signaling a shift towards targeted treatment approaches such as apoC-III inhibition in FCS management.
From a commercial perspective, the authorisation of Redemplo without requiring genetic confirmation of FCS could facilitate access for a broader population of clinically diagnosed FCS patients and support market uptake. Further growth opportunities may arise from future label expansion into broader hypertriglyceridemia populations across the US and EU, although Redemplo will face competition from other apoC-III inhibitors, including Tryngolza (olezarsen) and Waylivra (volanesorsen). However, the less-frequent administration of Redemplo relative to competing apoC-III therapies may provide a competitive advantage and support favorable positioning within the expanding FCS treatment market.
Ultimately, the approval of Redemplo strengthens the clinical validation of apoC-III inhibition, a therapeutic approach that could have implications beyond FCS and reshape the wider management of triglyceride disorders.
Go deeper with GlobalData
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.
